Prevail Provides Update on Parkinson’s Disease Treatment

- March 3rd, 2020

Prevail provided an update today on the advancement of its gene therapy program for patients with Parkinson’s disease with GBA1 mutations.

Prevail Therapeutics (NASDAQ:PRVL) provided an update today on the clinical advancement of its gene therapy program PR001 for patients with Parkinson’s disease with GBA1 mutations (PD-GBA).

As quoted in the press release:

Enrollment in the PR001 Phase 1/2 PROPEL clinical trial is progressing, patient dosing continues, and the Company is on track to report interim data on a subset of patients in the second half of 2020.

The Company will present on its clinical progress at the Cowen & Co. Annual Healthcare Conference in Boston today.

“We believe the PROPEL trial makes PR001 the first potentially disease-modifying gene therapy for PD-GBA patients to enter clinical trials. Its ongoing progress brings us a step closer to new treatment options for patients living with PD-GBA,” said Asa Abeliovich, M.D., Ph.D., Founder and Chief Executive Officer of Prevail. “We are excited about the potential of PR001 to slow or stop disease progression for PD-GBA patients.”

Click here to read the full press release.

  Life Science and Healthcare Investing report cover

Life Science and Healthcare Investing in 2021

 
The life science and healthcare market is a booming, multi-billion dollar industry. Read our 2021 life science outlook report!
 

Leave a Reply